TRUQAP (capivasertib)
TherapyAstraZeneca
TRUQAP (capivasertib) from AstraZeneca is an AKT inhibitor used in hormone receptor–positive breast cancer.
Approvals
1
Indications
1
Biomarkers
1
Mapped tests
1
Where this therapy is approved with a companion diagnostic
Each row represents a defined combination of indication, biomarker criteria, and TRUQAP. Select a testing pathway to see the eligible companion diagnostic tests.
Indication-specific approvals
Approvals where TRUQAP is tied to a specific indication and biomarker definition.
| Indication | Biomarker criteria | Notes | |
|---|---|---|---|
Metastatic hormone-sensitive prostate cancer (mHSPC) Solid Tumor | PTEN
| View testing pathway → |
Tumor-agnostic approvals
Approvals defined at the solid tumor level where biomarker criteria determine eligibility for TRUQAP.
No tumor-agnostic companion diagnostic approvals are currently mapped for this therapy.
Tests used in these approvals
These assays are identified in FDA labeling or sponsor materials as companion diagnostics or acceptable tests when considering TRUQAP for eligible patients.
Test
Ventana PTEN (SP218) RxDx Assay
Ventana Medical Systems, Inc. (Roche Diagnostics)
Method
IHC
Specimen
Tissue (FFPE)
1 approvalView test profile →